“Nano-flares” for the Analysis of Circulating Cancer Cells
Chad A. Mirkin， 博士，现担任巴拉克•奥巴马总统的科学与技术顾问委员会委员,国际纳米技术研究所主任，美国西北大学化学系George B. Rathmann教授，化工与生物工程系教授，生物医学工程系教授，材料科学与工程系教授，医学系教授。
Dr. Chad A. Mirkin, Director of the International Institute for Nanotechnology, the George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science & Engineering, and Professor of Medicine,Northwestern University
Icotinib, the First Target Therapeutic Drug for Cancer in China
Dr. Yinxiang Wang is the CEO and Chief Scientist Officer (CSO) of Zhejiang Beta Pharma, Inc. (ZBPI).As the CSO and one of the main innovators at ZBPI, Dr. Wang headed the research team which developed Icotinib Hydrochloride (Conmana®), a National Category-1 Novel Drug (NME). He was the project leader in charge of the pre-clinical and clinical phase I-III studies of Icotinib Hydrochloride as well as the commercialization of Icotinib.
Huanqin Dai, Ph.D.Assistant Professor ,Institute of Microbiology, Chinese Academy of Sciences Ruibao Ren, Ph.D. Deputy Director Shanghai Institute of Hematology Gil Alterovitz Ph.D.Assistant Professor Harvard Medical School
Haian Fu, PhDDirector of Emory Chemical Biology Discovery Center, Emory University Rudi Bao, Ph.D.Biology VP Hansoh Pharmaceuticals Group Shutao Wang Ph.D.Professor of Chemistry , Institute of Chemistry Chinese Academy of Sciences
Peng Liu Ph.D.Professor , Department of Biomedical Engineering, Tsinghua University Chengbin Wu Ph.D.VP of Biologics ChemPartner Zhuyin (Julie) Li Ph. D.Biology Team Leader, National Center for Advancing Translational Sciences; NIH, USA
Yao Chang Xu Ph.D.General manager of Hansoh Pharmaceutical Group Cai Li, Ph.D.Director and In Vivo Pharmacology China Lead of Merck Research Laboratories Joergen Nielsen, Ph.D.Principal Scientist , Assay Development and HTS, F. Hoffmann – La Roche, Basel, Switzerland
Qihui Shi, Ph.D.Professor ,Shanghai Jiao Tong University Chaoyong Yang, Ph.D.Professor ,Department of Chemical Biology, Xiamen University Jia-Ning Xiang, Ph.D.Head of Integrated Platform Science GlaxoSmithKline R&D China
Shuyi Si, Ph.D.Director of National Center of Screening for New Microbial Drugs Xu Lin, Ph.D.Professor Institute for Nutritional Sciences Bin Peng, Ph.D.Global Head (Executive Director) Oncology Translational Medicine (OTM) China, Novartis
Darren R. Link,Ph.D.Cofounder and Vice President, of Research & Development RainDance Technologies, Inc. Paul Tewson, Ph.D. Research Assiocate, of Montana Molecular Jonathan H Connick, Ph.D.Executive Director and Chair in vitro Pharmacology Council, Merck & Co.